Skip to main content
. Author manuscript; available in PMC: 2018 Nov 2.
Published in final edited form as: Clin Cancer Res. 2017 Oct 30;24(1):169–180. doi: 10.1158/1078-0432.CCR-17-1318

Figure 1. PIM1 expression is increased following treatment with anti-angiogenic agents in vivo.

Figure 1.

A) Mice harboring PC3 prostate cancer xenograft tumors were treated with vehicle, B20–4.1.1, or sunitinib. Serial sections from tumors were immunostained to measure hypoxia (hypoxyprobe; HP-1) and PIM1 (dashed lines delineate regions of hypoxia). B) Percent HP-1 and C) percent PIM1 positivity was determined by microscopy. D) PIM isoform expression in each cohort was assessed by immunoblotting. E) Mice injected with PC3/VEC or PC3/PIM1 cells were treated with vehicle, B20–4.1.1, or sunitinib, and tumor volume was measured over time. F) Percent tumor growth inhibition in PC3/VEC and PC3/PIM1 following treatment with sunitinib or B20. *, p < 0.05; n.s. = not significant.